2,3,9,10,16,17,23,24-octakis(3,6-dioxaheptyloxy)phthalocyanine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四吡咯及其衍生物
• 英文名称: 2,3,9,10,16,17,23,24-octakis(3,6-dioxaheptyloxy)phthalocyanine
• 英文别名: 6,7,15,16,24,25,33,34-Octakis[2-(2-methoxyethoxy)ethoxy]-2,11,20,29,37,38,39,40-octazanonacyclo[28.6.1.13,10.112,19.121,28.04,9.013,18.022,27.031,36]tetraconta-1,3,5,7,9,11,13,15,17,19(39),20,22,24,26,28(38),30(37),31,33,35-nonadecaene；6,7,15,16,24,25,33,34-octakis[2-(2-methoxyethoxy)ethoxy]-2,11,20,29,37,38,39,40-octazanonacyclo[28.6.1.13,10.112,19.121,28.04,9.013,18.022,27.031,36]tetraconta-1,3,5,7,9,11,13,15,17,19(39),20,22,24,26,28(38),30(37),31,33,35-nonadecaene
• 化学式: C₇₂H₉₈N₈O₂₄
• 分子量: 1459.61
• InChiKey: AXPXHJWEEQRWLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  104
• 可旋转键数：
  56
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  330
• 氢给体数：
  2
• 氢受体数：
  30

反应信息

• 作为产物：
  描述：

  1,2-Dibromo-4,5-bis-[2-(2-methoxy-ethoxy)-ethoxy]-benzene 在 lithium carbonate 作用下， 以 戊醇 为溶剂， 反应 66.0h， 以34%的产率得到2,3,9,10,16,17,23,24-octakis(3,6-dioxaheptyloxy)phthalocyanine
  参考文献：
  名称：

  The synthesis and photophysical properties of polyether substituted phthalocyanines of potential use in photodynamic therapy

  摘要：

  报告并讨论了一系列聚醚取代的金属和游离基酞菁的合成、光物理性质和单态氧产率，背景是这些化合物作为血红素卟啉衍生物（HpD）在癌症光动疗法（PDT）中潜在应用的可能性。采用纳秒激光闪光光解和脉冲辐射解法研究了酞菁的单重态。单重态光吸收最大值位于约510到525纳米，单重态形成的量子产率（ϕT）范围为0.14到0.32。单重态寿命在26到155微秒之间。酞菁的单重态（T1）向基态分子氧O23Σg-转移能量以产生单态氧O21ωg的效率很高，且在完全氘化苯中提供了建立平衡的证据，方程式（a）。通过时间分辨近红外发光测定的单态氧量子产率（ϕΔ）与单重态产率相当，这表明高比例的猝灭相遇导致单态氧的形成。金属酞菁的光物理性质依赖于中心金属离子的相对原子质量和磁性质。

  DOI：

  10.1039/a701079f

文献信息

• Phthalocyanines substituted with dendritic wedges: glass-forming columnar mesogens
  作者：Matthew Brewis、Guy J. Clarkson

  DOI：10.1039/a801799i

  日期：——

  Peripheral substitution of the phthalocyanine macrocycle with poly(aryl ether) dendritic wedges produces materials whose properties are dominated both by the columnar self-association of the phthalocyanine core and by the glass-forming character of the dendritic substituents.

  通过用聚芳醚树状楔形物对酞菁大环进行外围取代，制备出既受酞菁核心的柱状自组装特性主导，又受树状取代基玻璃形成特性的材料。
• Drug delivery system for hydrophobic drugs
  申请人：QLT, Inc.

  公开号：EP1900357A2

  公开（公告）日：2008-03-19

  Compositions comprising microaggregates containing hydrophobic drugs, as well as methods for their production, are described. Such microaggregates may include micelle structures or combinations thereof with liposomes, and constitute an effective delivery vehicle for a hydrophobic agent. Methods for microaggregate production include the use of preferred lipid compounds and processing conditions favoring the production of small aggregates for improved filter sterilization.

  本文介绍了由含有疏水性药物的微团聚体组成的组合物及其生产方法。这种微团聚体可包括胶束结构或其与脂质体的组合，并构成疏水性药物的有效递送载体。微团聚体的生产方法包括使用优选的脂质化合物和有利于生产小团聚体的加工条件，以提高过滤灭菌效果。
• Immuno-adjuvant PDT treatment of metastatic tumors
  申请人：——

  公开号：US20020022032A1

  公开（公告）日：2002-02-21

  Immuno-adjuvant photodynamic therapy to treat and prevent metastatic cancer is effected using photosensitizers in combination with immuno-adjuvants to destroy metastatic tumor cells.

  治疗和预防转移性癌症的免疫辅助光动力疗法是利用光敏剂与免疫辅助剂相结合来破坏转移性肿瘤细胞。
• Supports for photosensitizer formulations
  申请人：——

  公开号：US20020061330A1

  公开（公告）日：2002-05-23

  The invention is generally related to the field of formulating medicaments in association with a solid support. Such formulations comprising photosensitizers, and their use in photodynamic therapy, are also provided. Methods for the production of the medicament formulations are also disclosed.

  本发明一般涉及与固体支持物结合的药物制剂领域。本发明还提供了包含光敏剂的此类制剂及其在光动力疗法中的应用。本发明还公开了药物制剂的生产方法。
• Drug delivery systems for photodynamic therapy
  申请人：——

  公开号：US20020155089A1

  公开（公告）日：2002-10-24

  The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more block copolymers. Furthermore, the invention relates to processes for the production of, and application of, said formulations and compositions as photosensitizer drug delivery systems.

  本发明一般涉及光动力疗法领域，使用光敏剂和光敏剂的稳定制剂。这些制剂可用于将光敏剂作为药物、农业或工业制剂输送。本发明含有光敏剂的制剂和组合物包括一种或多种嵌段共聚物。此外，本发明还涉及生产和应用上述制剂和组合物作为光敏剂给药系统的工艺。